// App-Quantinova.ai

167 : Safety, PD-L1 expression, and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced gastric or gastroesophageal junction cancer.

Researchers

Presenter

  • Hyun Cheol Chung

Principal Investigators

  • Hendrik-Tobias Arkenau

  • Lucjan Wyrwicz

  • Do-Youn Oh

  • Keun-Wook Lee

  • Jeffrey R. Infante

  • Kevin M. Chin

  • Anja von Heydebreck

  • Yoon-Koo Kang

  • Howard Safran

Medical Centers

  • Yonsei Cancer Center, Yonsei University College of Medicine, Yonsei University Health System, Sinchon-dong, South Korea

  • Sarah Cannon Research Institute, London, United Kingdom

  • Maria Sklodowska-Curie Institute of Oncology, Warsaw, Poland

  • Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea, Republic of (South)

  • Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea

  • Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

  • EMD Serono, Inc, Billerica, MA

  • Merck KGaA, Darmstadt, Germany

  • Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

  • Brown University Urology, Providence, RI

Locations

  • Republic of South Korea

  • United Kingdom

  • Poland

  • United States

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gastroesophageal junction (GEJ) adenocarcinoma

Biomarkers

  • N/A

Drug/Treatment

  • Avelumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT01772004

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved